<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743897</url>
  </required_header>
  <id_info>
    <org_study_id>823833</org_study_id>
    <nct_id>NCT02743897</nct_id>
  </id_info>
  <brief_title>Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors</brief_title>
  <acronym>HCV</acronym>
  <official_title>Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine safety and effectiveness of transplanting kidneys
      from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant
      waitlist, who will then be treated with Zepatier after the single kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-labelled pilot clinical trial of Zepatier (MK-5172 and MK-8742/Grazoprevir + Elbasvir)
      in 40 HCV-negative subjects with end-stage renal disease receiving a kidney transplant from a
      HCV-positive donor. Eligible subjects will receive a kidney transplant from a deceased-donor
      with genotype 1 or 4 HCV, and then will receive 12 weeks of Zepatier after kidney
      transplantation when infection with HCV is confirmed in these kidney transplant recipients.
      Treatment will be complete after 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment sustained virologic response (SVR)</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR-12; negative HCV RNA 12 weeks after completing Zepatier therapy) / (number of subjects treated with Zepatier post-kidney transplantation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse events attributable to HCV therapy in post-kidney transplant patients post-kidney transplant patients.</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Zepatier (grazoprevir 100mg and elbasvir 50 mg) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zepatier is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zepatier</intervention_name>
    <arm_group_label>Zepatier (grazoprevir 100mg and elbasvir 50 mg) once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient

        Inclusion Criteria:

          -  Must be waitlisted for a kidney transplant

          -  Listed for an isolated kidney transplant with &lt;=913 days of accrued transplant waiting
             time and/or &lt;=913 days of dialysis time

          -  No available living kidney donor

          -  Blood group A, B, or O

          -  Between 40-65 years of age

          -  Have a panel reactive antibody level ≤97%

          -  Obtained agreement for participation from the patient's treating transplant
             nephrologist

          -  No evident contraindication to liver transplantation (Only subjects who would be
             eligible for a liver transplant if HCV caused them to experience liver failure will be
             enrolled in this study. To be deemed eligible for a liver transplant at Penn, all
             patients (not only study subjects) must have adequate cardiac function and must be
             examined by both a hepatologist and a liver transplant surgeon. These two requirements
             represent the major differences between evaluation processes for kidney and liver
             transplants.

          -  Able to travel to the University of Pennsylvania for routine post-transplant visits
             and study visits for a minimum of 6 months after transplantation

          -  Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation
             and Mitigation Strategy (REMS) following transplant due to the increased risk of birth
             defects and/or miscarriage

          -  Both men and women must agree to use at least one barrier method to prevent any
             secretion exchange

          -  No active illicit substance abuse

          -  Weigh at least 50kg

          -  Inclusion criteria for treatment (not for entry as study patient) will include any
             detectable HCV RNA level

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Hepatocellular carcinoma

          -  Patients with primary focal segmental glomerulosclerosis (FSGS), FSGS recurring after
             previous transplant, or disease process with increased risk of causing early graft
             failure as assessed by the transplant nephrologist and/or the investigator team

          -  HIV positive

          -  HCV RNA positive (can be isolated HCV antibody positive provided the subject has no
             history of previously treated HCV)

          -  Hepatitis b surface antigen positive

          -  Any other chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)
             with abnormal liver enzymes

          -  Persistently elevated liver transaminases

          -  Blood group AB(due to short expected waiting time on the kidney transplant waiting
             list)

          -  Significant hepatic fibrosis on screening elastography (≥F2 fibrosis)

          -  Pregnant or nursing (lactating) women

          -  Known allergy or intolerance to tacrolimus that would require post-transplant
             administration of cyclosporine, rather than tacrolimus given the drug-drug interaction
             between cyclosporine and Zepatier

          -  Waitlisted for a multi-organ transplant (e.g., pancreas-kidney, heart-kidney,etc.)

          -  Cardiomyopathy (e.g., left-ventricular heart failure, pulmonary hypertension) that
             would preclude liver transplantation, as per the discretion of the transplant
             hepatologist (dg) and abdominal transplant surgeon who will evaluate the patient.

        Donor Organ Criteria

        Inclusion criteria:

          -  Detectable HCV RNA

          -  Genotype 1 or 4 HCV

          -  Age ≤60 years

          -  Kidney donor profile index (KDPI) score ≤0.856

        Exclusion criteria:

          -  Diabetes mellitus I or II

          -  Anatomical issues in the kidney allograft that raise the risk of post-transplant
             complications (e.g. number or length of renal arteries or veins)

          -  Confirmed HIV positive

          -  Confirmed HBV positive (positive hepatitis B surface antigen and/or HBV DNA)

          -  Known previously failed treatment for HCV using a regimen with a direct-acting
             antiviral (can have received interferon monotherapy and/or interferon + ribavirin
             combination therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Goldberg, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hospital of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Reese, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hospital of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Goldberg, MD, MSCE</last_name>
    <phone>(307) 22-THINK</phone>
    <email>thinker@med.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Reese, MD, MSCE</last_name>
    <phone>(307) 22-THINK</phone>
    <email>thinker@med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.questdiagnostics.com/testcenter/testguide.action?dc=TS_HCV_NS5A_Genotype&amp;tabview=true</url>
    <description>Quest Diagnostics, Inc. (December 2014). Test summary guide. Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance.</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc637c8f-9669-4bc5-8787-1fd5abaa588e.</url>
    <description>Sandoz, Inc. (May 2015) Ribavirin capsule. Highlights of Prescribing Information. 2015.</description>
  </link>
  <reference>
    <citation>Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.</citation>
    <PMID>25467560</PMID>
  </reference>
  <reference>
    <citation>Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21;385(9973):1075-86. doi: 10.1016/S0140-6736(14)61795-5. Epub 2014 Nov 11. Erratum in: Lancet. 2015 Mar 21;385(9973):1074.</citation>
    <PMID>25467591</PMID>
  </reference>
  <reference>
    <citation>Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.</citation>
    <PMID>25895428</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.</citation>
    <PMID>25909356</PMID>
  </reference>
  <reference>
    <citation>O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int. 2012 Aug;25(8):825-9. doi: 10.1111/j.1432-2277.2012.01498.x. Epub 2012 May 30.</citation>
    <PMID>22643162</PMID>
  </reference>
  <reference>
    <citation>Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5. Erratum in: Lancet. 2015 Nov 7;386(10006):1824.</citation>
    <PMID>26456905</PMID>
  </reference>
  <reference>
    <citation>Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting Hepatitis C-Positive Kidneys. N Engl J Med. 2015 Jul 23;373(4):303-5. doi: 10.1056/NEJMp1505074.</citation>
    <PMID>26200976</PMID>
  </reference>
  <reference>
    <citation>Reddy KR FS, et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Hepatology. 2014;60:200A</citation>
  </reference>
  <reference>
    <citation>Van Deerlin, V. (December 2015). Hepatitis C Virus Genotyping (GenMark Assay) Validation Summary</citation>
  </reference>
  <reference>
    <citation>Pawlak R RJ, Maranan G, Michel-Treil V, Schutzbank T. A Comparative Evaluation of the Siemens VERSANT HCV Genotype 2.0 (LiPA) and GenMark eSensor HCV Direct Genotyping Tests. CVS 2013 Covance; 2013</citation>
  </reference>
  <reference>
    <citation>Dahl A HD, Ogorek T, Hansen G. Comparison of the GenMark Direct Genotype Assay with the LiPA Genotype Assay Using a Diverse Spectrum of HCV Clinical Samples Encountered in a High Risk Inner City HCV Population. CVS 2013 Hennepin; 2013.</citation>
  </reference>
  <reference>
    <citation>Woodberry M SK, Castor J, Cook L, Jerome K. Genotyping of Hepatitis C Virus by the Genmark DX Esensor HCVG Direct Test. CVS 2013 UW-Seattle 2013</citation>
  </reference>
  <reference>
    <citation>U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (June 2010). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.</citation>
  </reference>
  <reference>
    <citation>Merck Sharp &amp; Dohme Corporation (January 2016). ZEPATIER™ tablets. Highlights of Prescribing Information. 2016.</citation>
  </reference>
  <reference>
    <citation>Merck Sharp &amp; Dohme Corporation (July 2015). Elbasvir (MK-8742). Investigator's Brochure (8th Ed.). 2015.</citation>
  </reference>
  <reference>
    <citation>Merck Sharp &amp; Dohme Corporation (July 2015). Grazoprevir (MK-5172). Investigator's Brochure (10th Ed.). 2015.</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>end-stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Elbasvir-grazoprevir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

